Novartis stumbles in Q2 as COVID-19 impacts sales

That includes its wet AMD drug Lucentis (ranibizumab), which fell 25% to bring in $401m in the quarter.

Bayer shares dip as Novartis gets EU okay for Beovu in wet AMD

aflibercept) squaring off against Novartis’ older drug Lucentis (ranibizumab), the first VEGF inhibitor for wet AMD to reach the market. ... Novartis’ sales of Lucentis managed a slight gain overall in 2019 to just over $2bn, but fell slightly in the

Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

Lucentis was the first VEGF inhibitor to reach the market for wet AMD and grew quickly into a blockbuster product with sales of around $3.7bn last year. ... Alteogen and Momenta/Mylan have versions of Eylea in development, while Coherus and Xbrane Pharma

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

The green light for Beovu (brolucizumab) is a boost for Novartis as it tries to defend its  wet AMD franchise, currently represented by $2bn-plus VEGF inhibitor product  Lucentis (ranibizumab) which ... That compares to four to eight week dosing with

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]